Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model
- 1 October 1992
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (10) , 2334-2337
- https://doi.org/10.1128/aac.36.10.2334
Abstract
The purpose of this study was to develop a pharmacodynamic model to describe the dependency of the rate of Staphylococcus aureus killing upon the concentration of daptomycin. A range of free (unbound) daptomycin concentrations ranging from 0.12 to 27 times the MIC were simulated in the peripheral compartment of a two-compartment pharmacokinetic model. Log-linear regression of free daptomycin concentrations versus growth or kill rate constants showed a significant correlation (r = -0.90; P less than 0.001). A Lineweaver-Burk plot of the reciprocal transformation of these data yielded a poor fit (r = -0.38; P greater than 0.05). When a Lineweaver-Burk-type regression analysis was performed on the reciprocal of the change in the rate constant rather than the rate constant itself, the result demonstrated good correlation (r = 0.90; P less than 0.0001). The observations were also well described by a sigmoidal maximum plateau pharmacologic effect model, in which the pharmacologic effect of daptomycin is a reduction in the bacterial exponential growth rate constant from the baseline in the absence of antibiotic to a lower (positive) growth or (negative) death rate constant observed in the presence of antibiotic. These data confirm that daptomycin exhibits concentration-dependent killing over a wide range of free daptomycin concentrations relative to the MIC and suggest that this is a saturable process similar to the Michaelis-Menten pharmacokinetic elimination of certain drugs.Keywords
This publication has 13 references indexed in Scilit:
- Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic modelAntimicrobial Agents and Chemotherapy, 1990
- Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studiesDiagnostic Microbiology and Infectious Disease, 1990
- Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycinAntimicrobial Agents and Chemotherapy, 1989
- Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1988
- Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studiesAntimicrobial Agents and Chemotherapy, 1987
- Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendationsAntimicrobial Agents and Chemotherapy, 1987
- In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- In vitro activity of LY146032 (Daptomycin), a new peptolideEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocciAntimicrobial Agents and Chemotherapy, 1987
- In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibioticAntimicrobial Agents and Chemotherapy, 1986